<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol J</journal-id><journal-title>Virology Journal</journal-title><issn pub-type="epub">1743-422X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1743-422X-4-85</article-id><article-id pub-id-type="pmid">17822534</article-id><article-id pub-id-type="doi">10.1186/1743-422X-4-85</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Akl</surname><given-names>Haidar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>haidaakl@ulb.ac.be</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Badran</surname><given-names>Bassam</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bbadran@ulb.ac.be</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Dobirta</surname><given-names>Gratiela</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>adobirta@ulb.ac.be</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Manfouo-Foutsop</surname><given-names>Germain</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mfoutsop@hotmail.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Moschitta</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>maria.moschitta@hotmail.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Merimi</surname><given-names>Makram</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mmerimi@hotmail.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Burny</surname><given-names>Ars&#x000e8;ne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>burny.a@fsagx.ac.be</email></contrib><contrib id="A8" corresp="yes" contrib-type="author"><name><surname>Martiat</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pmartiat@ulb.ac.be</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Willard-Gallo</surname><given-names>Karen E</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kwillard@ulb.ac.be</email></contrib></contrib-group><aff id="I1"><label>1</label>Laboratory of Experimental Hematology, Institut Jules Bordet, Universit&#x000e9; Libre de Bruxelles (ULB), 121, Boulevard de waterloo, 1000, Brussels, Belgium</aff><aff id="I2"><label>2</label>Molecular Immunology Unit, Institut Jules Bordet, Universit&#x000e9; Libre de Bruxelles (ULB), 127, Boulevard de waterloo, 1000, Brussels, Belgium</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>6</day><month>9</month><year>2007</year></pub-date><volume>4</volume><fpage>85</fpage><lpage>85</lpage><ext-link ext-link-type="uri" xlink:href="http://www.virologyj.com/content/4/1/85"/><history><date date-type="received"><day>31</day><month>7</month><year>2007</year></date><date date-type="accepted"><day>6</day><month>9</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Akl et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Akl et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Akl Haidar haidaakl@ulb.ac.be </dc:author><dc:title> Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>Virology Journal 4(1): 85-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1743-422X(2007)4:1&#x0003c;85&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1743-422X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>HTLV-I infected CD4<sup>+ </sup>T-cells lines usually progress towards a CD3<sup>- </sup>or CD3<sup>low </sup>phenotype. In this paper, we studied expression, kinetics, chromatin remodeling of the CD3 gene at different time-points post HTLV-I infection.</p></sec><sec><title>Results</title><p>The onset of this phenomenon coincided with a decrease of <italic>CD3</italic>&#x003b3; followed by the subsequent progressive reduction in <italic>CD3</italic>&#x003b4;, then <italic>CD3</italic>&#x003b5; and <italic>CD3</italic>&#x003b6; mRNA. Transient transfection experiments showed that the <italic>CD3</italic>&#x003b3; promoter was still active in CD3<sup>- </sup>HTLV-I infected cells demonstrating that adequate amounts of the required transcription factors were available. We next looked at whether epigenetic mechanisms could be responsible for this progressive decrease in CD3 expression using DNase I hypersensitivity (DHS) experiments examining the <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; promoters and the <italic>CD3</italic>&#x003b4; enhancer. In uninfected and cells immediately post-infection all three DHS sites were open, then the CD3&#x003b3; promoter became non accessible, and this was followed by a sequential closure of all the DHS sites corresponding to all three transcriptional control regions. Furthermore, a continuous decrease of <italic>in vivo </italic>bound transcription initiation factors to the <italic>CD3</italic>&#x003b3; promoter was observed after silencing of the viral genome. Coincidently, cells with a lower expression of CD3 grew more rapidly.</p></sec><sec><title>Conclusion</title><p>We conclude that HTLV-I infection initiates a process leading to a complete loss of CD3 membrane expression by an epigenetic mechanism which continues along time, despite an early silencing of the viral genome. Whether CD3 progressive loss is an epiphenomenon or a causal event in the process of eventual malignant transformation remains to be investigated.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>HTLV-I infection can lead to the development of adult T-cell leukemia/lymphoma (ATLL) in 2&#x02013;5% of infected individuals depending upon geographic location and exposure to etiologic factors. It is currently thought that tumors develop from a persistently infected T-cell reservoir, which can be amplified by cytokine-induced activation leading to viral gene expression, cellular proliferation and survival of some expanded cells. Viral gene expression has been implicated in the disruption of various normal cellular processes, including activation, growth, and apoptosis, the latter allowing accumulation of abnormalities leading to cellular transformation. Several viral proteins have been shown to play an important role in tumor progression by modulating transcription factors. The pleiotropic viral protein Tax mediates the NF-&#x003ba;B activation resulting in abnormal cytokine and cytokine receptor expression[<xref ref-type="bibr" rid="B1">1</xref>]. Sumoylation and ubiquitination of Tax are critical for Tax mediated transcriptional activity[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. The viral protein p12<sup>I </sup>stimulates calcium release from the endoplasmic reticulum, which induces NFAT transcription factors leading to T-cell activation[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. The viral protein HBZ represses c-Jun mediated transcription by inhibiting its DNA binding activity[<xref ref-type="bibr" rid="B6">6</xref>].</p><p>A keystone of the antigen-specific immune response is the T-cell receptor (TCR)/CD3 complex. Infected CD4<sup>+ </sup>lines and T-cells from patients with ATLL are characterized by a CD3<sup>- </sup>or CD3<sup>low </sup>phenotype [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. In a previous work[<xref ref-type="bibr" rid="B10">10</xref>] we have shown that HTLV-I infected cells acquired a profound decrease of intracellular calcium levels in response to ionomycin, timely correlated with decreased CD7 and CD3 expression. This perturbation induced Akt and Bad phosphorylation via activation of PI3K. The activation of the Akt/Bad pathway generates a progressive resistance to apoptosis, at a time HTLV-I genes expression is silenced. Since dysregulation of calcium flux after T-cell activation has been suggested as a possible consequence of absence of CD3 expression[<xref ref-type="bibr" rid="B11">11</xref>]. We decided to investigate the mechanisms responsible for the loss of CD3 expression, its kinetics and its timely relationship with viral gene expression.</p><p>Experimental infection of CD4<sup>+ </sup>T cells with HTLV-I was known to progressively downregulate <italic>CD3 </italic>genes transcripts, eventually leading to a CD3<sup>- </sup>surface phenotype after 200 days of <italic>in vitro </italic>infection [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]; however, the sequence of CD3 genes loss of expression had not been investigated. Previous data from our laboratory showed that CD3 membrane expression was downmodulated after experimental infection of CD4<sup>+ </sup>T cells with HIV-1 [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B17">17</xref>], HIV-2[<xref ref-type="bibr" rid="B18">18</xref>], as well as in patients with CD3<sup>- </sup>CD4<sup>+ </sup>T-cell lymphoma mediated hypereosinophilic syndrome [<xref ref-type="bibr" rid="B19">19</xref>], all linked to a specific defect in <italic>CD3</italic>&#x003b3; gene transcripts. All T-lymphotropic viruses induce CD3 downregulation in the absence of a generalized suppression of host protein synthesis.</p><p>The HTLV LTR responds to T cell-activation signals[<xref ref-type="bibr" rid="B20">20</xref>], which suggests an important relationship between the regulation of viral gene transcription and the TCR/CD3-controlled antigen activation pathway. This study demonstrates that HTLV-I associated loss of CD3 expression is also linked to an initial loss of <italic>CD3</italic>&#x003b3; gene transcripts, ultimately leading to a CD3<sup>- </sup>phenotype. However, we show that the initial <italic>CD3</italic>&#x003b3; transcripts decrease is followed by a subsequent progressive and sequential reduction in <italic>CD3</italic>&#x003b4;, <italic>CD3</italic>&#x003b5; and <italic>CD3</italic>&#x003b6; genes transcription, going on after early viral genes silencing. Our experiments also demonstrate that these phenomena occur through chromatin remodeling and progressive closure of the CD3 genes promoter sites and are not the results of transcription factors depletion. Finally, this loss of CD3 expression is timely associated with a growth advantage, but further experiments will be needed to determine whether there is a causal relationship between these two observations.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Cell culture conditions and reagents</title><p>The WE17/10 cell line is a human IL-2 dependent CD4<sup>+ </sup>T cell line[<xref ref-type="bibr" rid="B14">14</xref>] that was established and is maintained in RPMI 1640 containing 20% fetal bovine serum, 1.25 mM L-glutamine, 0.55 mM L-arginine, 0.24 mM L-asparagine, and 100 units of recombinant human IL-2 per ml. The MT-2 cell line was derived by co-culturing normal umbilical cord leukocytes with donor leukemic T-cells from an HTLV-I infected patient [<xref ref-type="bibr" rid="B21">21</xref>]. WE17/10 cells were co-cultured with irradiated MT-2 cells at a ratio of 1:1 to generate HTLV-I infected WE17/10 cell lines. The human B lymphocyte line, GM-607, was obtained from the Human Genetic Cell Repository run by Coriell Institute, Camden NJ). The HTLV-1-transformed T-cell lines (C91-PL, MT-2), were obtained from MT-2, C91-PL and GM-607 cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum and ATL-derived culture (PaBe).</p></sec><sec><title>Southern blot</title><p>We used a standard southern blot protocol. The genomic DNA was digested with E<italic>co</italic>RI (no cut into the HTLV-I provirus) or S<italic>ac</italic>I (cut once into the HTLV-I LTR) and electrophoresed in an agarose gel then transferred to nylon membrane (Amersham International, Buckinghamshire, UK). The filters were hybridized with radiolabeled probe : a <italic>Kpn</italic>I fragment[<xref ref-type="bibr" rid="B22">22</xref>], corresponding to a 2.9 kb fragment beginning in the <italic>pro </italic>gene and ending in the <italic>env </italic>gene, at 65&#x000b0;C for 12 hours, washed in buffers, and then exposed to X-ray film at -80&#x000b0;C.</p></sec><sec><title>Flow Cytometry</title><p>Cells were analyzed for CD3 surface expression by flow cytometry as previously described[<xref ref-type="bibr" rid="B17">17</xref>]. Briefly, cells were labeled with the murine monoclonal antibody Leu4a (BD Biosciences, Erembodegen, Belgium) in a two-step process using 1 &#x003bc;g/ml of the primary antibody to ensure saturation binding followed by the manufacturer's recommended dilution of fluorescein-conjugated goat anti-mouse immunoglobulin (BD Biosciences). The labeled cells were fixed in 2% paraformaldehyde, and fluorescence was analyzed on a FACS Caliber (BD Biosciences).</p></sec><sec><title>Transient transfection</title><p>WE17/10 cells (uninfected and HTLV-I infected) were transiently transfected using standard DEAE-dextran protocols with wild-type (pH&#x003b3;3-wt) promoter construct as previously described[<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>Identification of Dnase I hypersensitive sites</title><p>Isolation and DNase I digestion of nuclei was performed using a method previously described [<xref ref-type="bibr" rid="B24">24</xref>]. Briefly, the cells were washed in PBS and resuspended in cell lysis buffer (60 mM KCl, 15 mM NaCl, 5 mM MgCl<sub>2</sub>, 10 mM Tris pH 7.4, 300 mM sucrose, 0.1 mM EGTA, and 0.1% NP-40) to isolate the nuclei. The nuclei were then resuspended in 1 ml of nuclear digestion buffer (60 mM KCl, 15 mM NaCl, 5 mM MgCl<sub>2</sub>, 10 mM Tris pH 7.4, 300 mM sucrose, and 0.1 mM EGTA). Nuclei from 20 &#x000d7; 10<sup>6 </sup>cells were digested for 3 minutes at 22&#x000b0;C using increments of DNase I (Roche Diagnostics) from 0 to 28 U/ml. The reaction was stopped by adding nuclear lysis buffer (300 mM sodium acetate, 5 mM EDTA pH 7.4, 0.5% SDS) containing 0.1 mg/ml proteinase K and incubating for 5 min at 55&#x000b0;C then overnight at 37&#x000b0;C. Genomic DNA was subsequently isolated using standard phenol chloroform extraction techniques.</p><p>Genomic DNA was digested with BglI for the <italic>CD3</italic>&#x003b4; promoter, BamHI for the <italic>CD3</italic>&#x003b4; enhancer and SacI for the <italic>CD3</italic>&#x003b3; promoter prior to standard Southern blot analysis. Promoter probes were amplified by PCR using the following primer pairs:</p><p><italic>CD3&#x003b3; promoter: </italic>forward, 5'-CACCTGCTGAAACTGAGCTG-3', reverse, 5'-TCCCAGACAGTGGAGGAGTT-3';</p><p><italic>CD3&#x003b4;promoter: </italic>forward, 5'-GTTCCTCTGACAGCCTGAGC-3' and reverse 5'-TTTTAGGCCTGATGGCCTCT-3'.</p><p>The probe used to detect the <italic>CD3</italic>&#x003b4; enhancer was a BamHI digest of the human <italic>CD3</italic>&#x003b4; cDNA (NCBI accession # BC070321).</p></sec><sec><title>RT-PCR</title><p>Total RNA was isolated from cells using the TriPure Isolation Reagent (Roche Applied Science) in a single-step extraction method. Standard reverse transcription was performed using 1 &#x003bc;g of total RNA at 42&#x000b0;C for 45 minutes and 50 ng of the resulting cDNA was used per PCR reaction. The primer pairs used to amplify the individual <italic>CD3 </italic>genes have been previously described[<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>] and are as follows:</p><p><italic>CD3</italic>&#x003b3;: forward 5'-CATTGCTTTGATTCTGGGAACTGAATAGGAGGA-3', reverse 5'-GGCTGCTCCACGCTTTTGCCGGAGACAGAG-3';</p><p><italic>CD3</italic>&#x003b4;: forward 5'-TTCCGGTACCTGTGAGTCAGC-3', reverse 5'-GGTACAGTTGGTAATGGCTGC-3'.</p></sec><sec><title>Quantitative real-time RT-PCR</title><p>Real-time RT-PCR was performed using a TaqMan Gene Expression Assay for each of the individual CD3 genes (CD3&#x003b6; HS00609512, CD3&#x003b5; HS00167894, CD3&#x003b3; HS00173941 and CD3&#x003b4; HS00174158; Applied Biosystems, Lennik, Belgium). Eukaryotic translation elongation factor1 &#x003b1;(EF-1-&#x003b1;) and cancer susceptibility candidate 3 (MLN51) were used as CD4+ T cell specific endogenous reference genes as described by Hamalainen <italic>et al</italic>[<xref ref-type="bibr" rid="B27">27</xref>]. Relative quantification was used to compare the changes in CD3 mRNA levels using the endogenous genes (EF-1-&#x003b1; and MLN51) as a normalizer and uninfected WE17/10 cells as a calibrator. The individual CD3 genes were normalized to the endogenous controls and the values are expressed as the quantity relative to the uninfected WE17/10 cell line. Biological duplicates were performed for all genes tested.</p></sec><sec><title>EMSA</title><p>Nuclear extracts were prepared from 2 &#x000d7; 10<sup>7 </sup>cells, and EMSA experiments were performed as described previously[<xref ref-type="bibr" rid="B17">17</xref>]. The radiolabeled oligonucleotide probe used for nuclear protein binding was an oligonucleotide encoding wild-type Sp&#x003b3;<sub><bold>1</bold></sub>/CD3&#x003b3;Inr binding site: Sp&#x003b3;<sub><bold>1</bold></sub>/CD3&#x003b3;Inr<sub><bold>wt</bold></sub>, 5'-GTGATGGGTGGAGCCAGTCTAG-3'[<xref ref-type="bibr" rid="B23">23</xref>]. The oligonucleotide bound complexes were separated on a 6% Tris-glycine-EDTA polyacrylamide gel migrated overnight at 50 V, and the radiolabeled protein complexes were detected by autoradiography.</p></sec><sec><title>Chromatin immunoprecipitation (ChIP) assay</title><p>The ChIP assay was performed as previously described[<xref ref-type="bibr" rid="B28">28</xref>] using the kit purchased from Upstate Biotechnology generally following the manufacturer's protocol. Uninfected and HTLV-I-infected WE17/10 cells were fixed with 1.5% formaldehyde for 10 min at 37&#x000b0;C. Chromatin was isolated, sheared using a Bioruptor (Diagenode), and immunoprecipitated with Abs directed to ac-H4, HDAC1, Sp1 (SC-59X), Sp3 (SC-644X), TFIID (SC-204X) (all from Santa Cruz Biotechnology), or control rabbit IgG (Upstate Biotechnology). Cross-linking was reversed by heating, and the proteins were removed subsequently by proteinase K digestion. The presence of selected DNA sequences in the immunoprecipitated DNA was assessed by PCR using the following primer pair Sp&#x003b3;<sub><bold>1</bold></sub>, CD3&#x003b3;<sub>Inr</sub>, and Sp&#x003b3;<sub><bold>2 </bold></sub>(205-bp product), forward, 5'-GGGTTCTTGCCTTCTCTCTCAA-3', reverse, 5'-CCCCTAGTAGGCCCTTACCTT-3'.</p><p>The amplified <sup>32</sup>P-labeled PCR product was separated on a 6% acrylamide gel and detected by autoradiography.</p></sec></sec><sec><title>Results</title><sec><title>CD3 loss after HTLV-I infection is linked to a sequential reduction in CD3 gene transcripts</title><p>The cell lines were derived from the IL-2 dependent CD4<sup>+ </sup>T cell line WE17/10 infected by the HTLV-I viruses produced by the MT-2 cell line. The latter, used as virus source, contains 8 complete or defective proviral genomic integrations some defective proviral genomes being able to produce viral RNA transcripts. The most dominant species of unintegrated viral DNA was 3.7 kb in size; it hybridized to a full-length HTLV-1 DNA probe but not to a <italic>KpnI </italic>viral DNA fragment beginning in the <italic>pro </italic>gene and ending in the <italic>env </italic>gene[<xref ref-type="bibr" rid="B29">29</xref>] that is absent from a defective proviral genome that has been previously identified in MT-2 cells.</p><p>At 2 months p.i. using <italic>Eco</italic>RI, which does not cut within the 9 kb of the HTLV-I genome, the complete provirus probe revealed a smear witnessing a polyclonal integration of the provirus in the WE17/10 infected cells (Figure <xref ref-type="fig" rid="F1">1A</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Proviral integration, CD3 surface expression and relative <italic>CD3 </italic>gene expression over time after HTLV-I infection of WE17/10 cells</bold>. <italic>A</italic>, HTLV-I proviral genome analyses of WE/HTLV cell line by Southern blot. the complete provirus probe was hybridized to the WE/HTLV (at 3 weeks, 4 and 7 months p.i.) genomic DNA digested with E<italic>co</italic>RI. <italic>B</italic>, the K<italic>pn</italic>I fragment probe was hybridized to the (at 7 months p.i.) genomic DNA digested with S<italic>ac</italic>I. <italic>C</italic>, the K<italic>pn</italic>I fragment probe was hybridized to the (at 7 months p.i.) genomic DNA digested with E<italic>co</italic>RI. MT-2 and uninfected WE17/10 cell lines were used as positive and negative control respectively. <italic>D</italic>, TCR/CD3 surface expression over time after HTLV-I infection of WE17/10 cells. profiles showing the distribution of immunofluorescence from anti-CD3 antibody staining in a parallel antibody labeling experiment. Uninfected and HTLV-I infected cells were thawed from the frozen cell line bank at 5, 10, 40, 48, and 58 weeks p.i. TCR/CD3<sup>low </sup>cells are identified as cells that fall below the minimum fluorescence intensity defined by the positive control but do not lie within the region defined by the negative control. TCR/CD3<sup>hi </sup>cells fall within the region defined by mock-infected cells, and TCR/CD3<sup>- </sup>cells fall within the region designated by the negative control. <italic>E</italic>, Histograms representation of relative <italic>CD3 </italic>gene expression in HTLV-I infected cells at various times p.i. determined by real time RT-PCR in relation to the percentage of surface TCR/CD3<sup>+ </sup>cells determined by flow cytometry. All percentages were calculated relative to uninfected cells (100% positive). GM-607 B cell line was used as a negative control.</p></caption><graphic xlink:href="1743-422X-4-85-1"/></fig><p>At 4 months p.i. the same experiment showed three bands of 18, 14 and 11 kb. At 7 months p.i. Only the 18 an 14 kb bands were evident suggesting at that time a biclonal proliferation of infected cells in the culture. Using the <italic>Kpn</italic>I fragment as probe we detected a 9 kb band when the genomic DNA was digested with S<italic>ac</italic>I, an enzyme cutting once in each HTLV-I LTR (Figure <xref ref-type="fig" rid="F1">1B</xref>). The same <italic>Kpn</italic>I probe revealed an 18 Kb fragment after E<italic>co</italic>RI DNA digestion (Figure <xref ref-type="fig" rid="F1">1C</xref>). Our data suggests that a WE17/10 clone, harboring one complete and one incomplete HTLV-I provirus, not detected by the <italic>Kpn</italic>I probe, has a significant growth advantage. This is in accordance with the fast growing cultures observed later on.</p><p>ATLL patients are routinely characterized as having a CD3<sup>- </sup>or CD3<sup>low </sup>phenotype [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Experimental infection of CD4<sup>+ </sup>T cells with HTLV-I and HTLV-II[<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] has also been associated with defects in TCR/CD3 expression and function. We have tested the HTLV-I infected cell lines MT-2, C91, WE/HTLV and an ATLL derived cell line PaBe for their TCR/CD3 surface expression. All the cells had a CD3<sup>- </sup>or CD3<sup>low </sup>phenotype (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>).</p><p>For WE/HTLV we have studied the kinetics of the CD3 surface expression loss. Initially, during the acute phase of infection, cell growth was slowed down by virus production and a significant cytopathic effect. At this time, assessment of TCR/CD3 surface expression by flow cytometry was difficult. Chronically infected cells, appearing around 3 weeks p.i., returned to a normal growth rate and expressed CD3 levels similar to the mock-infected control until 5 weeks p.i., the time when CD3<sup>low </sup>expressing cells first emerged.</p><p>Cryopreserved cells from different stages of the primary infection were thawed and CD3 surface density was quantified in a parallel experiment to ensure that the detected changes were not attributable to variation in antibody labeling experiments (Figure <xref ref-type="fig" rid="F1">1D</xref>). A significant reduction in CD3 density on the infected cell surface, corresponding to the CD3<sup>low </sup>phenotype, was detected at 6 to 10 weeks p.i. The cells remained CD3<sup>low </sup>until receptor negative cells began to emerge around 7 months p.i. followed by the complete loss of surface expression at approximately one year p.i. Thus, CD3 expression on chronically HTLV-I infected cells (WE/HTLV) decreased in a progression from CD3<sup>hi </sup>to CD3<sup>low </sup>to CD3<sup>-</sup>, similar albeit slower than that previously described for HIV-infected cells[<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. The mock-infected cells, carried in parallel passages, continuously maintained CD3<sup>hi </sup>expression.</p><p>A previous study[<xref ref-type="bibr" rid="B13">13</xref>] found that all four CD3 chains transcripts (<italic>CD3</italic>&#x003b3;, &#x003b4;, &#x003b5; and &#x003b6;) were lost after HTLV-I infection <italic>in vitro</italic>, but these experiments did not provide insight into the order of their loss. Our previous experiments have shown that TCR/CD3 surface receptors are down-modulated after infection with HIV-1[<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B17">17</xref>] and HIV-2[<xref ref-type="bibr" rid="B18">18</xref>] linked to an initial reduction in <italic>CD3</italic>&#x003b3; gene transcripts. We therefore asked whether the <italic>CD3</italic>&#x003b3; gene was also initially targeted after HTLV-I infection and found that its specific decrease of transcription precedes the progressive loss of surface CD3 expression on HTLV-I infected cells.</p><p>A real time RT-PCR assay for quantification of all four CD3 gene transcripts revealed that the loss of TCR/CD3 complex at the cell surface occurs quite later than the loss of <italic>CD3</italic>&#x003b3; transcripts (Figure <xref ref-type="fig" rid="F1">1E</xref>). Initially, at 5 weeks p.i. there is a 25% decrease in <italic>CD3</italic>&#x003b3;, <italic>CD3</italic>&#x003b4; and <italic>CD3</italic>&#x003b5; transcripts observed in infected cells, shown by flow cytometry to express ~95% TCR/CD3<sup>+ </sup>surface complexes (relative to the uninfected controls). Subsequently, a precipitous drop of about 80% in <italic>CD3</italic>&#x003b3; transcripts appears while the density of the TCR/CD3 on the cell surface is ~70%. This erosion in <italic>CD3</italic>&#x003b3; transcript numbers progresses until all of the cells are <italic>CD3</italic>&#x003b3; and surface CD3 negative (&#x000b1; 9&#x02013;12 mo. p.i.). This loss of <italic>CD3</italic>&#x003b3; gene expression is followed by a steady decrease in <italic>CD3</italic>&#x003b4; transcripts followed by a slower but also progressive reduction in <italic>CD3</italic>&#x003b5; and <italic>CD3</italic>&#x003b6; transcripts. Maintained continuously <italic>in vitro</italic>, the HTLV-I infected cells eventually become negative for <italic>CD3</italic>&#x003b4; as well as <italic>CD3</italic>&#x003b3; transcripts. The level of <italic>CD3</italic>&#x003b5; and <italic>CD3</italic>&#x003b6; transcripts remains ~25% in the CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>- </sup>cells even after more than three years p.i. In MT-2 cells <italic>CD3</italic>&#x003b3;, <italic>CD3</italic>&#x003b4; and <italic>CD3</italic>&#x003b5; transcripts are completely lost while the <italic>CD3</italic>&#x003b6; transcripts are still expressed but at a very low level (data not shown).</p></sec><sec><title>The CD3&#x003b3; promoter can be activated in CD3<sup>- </sup>HTLV-I infected WE17/10 cells</title><p>In an effort to investigate the full-length <italic>CD3</italic>&#x003b3; promoter activity in the HTLV-I infected cells after the loss of <italic>CD3</italic>&#x003b3; gene expression we used our previously described construct (pH&#x003b3;3-wt)[<xref ref-type="bibr" rid="B23">23</xref>] in a transient reporter assay (Figure <xref ref-type="fig" rid="F2">2</xref>). pH&#x003b3;3-wt was transfected into uninfected and HTLV-I infected WE17/10 cells. Interestingly, in CD3&#x003b3;-&#x003b4;+ and CD3&#x003b3;-&#x003b4;- HTLV-I infected WE17/10 cells, the <italic>CD3</italic>&#x003b3; promoter activity was similar to that of uninfected WE17/10 cells. It was over 2.5 fold of the activity measured for the pGL3 plasmid basic vector (pGL3-BV). The <italic>CD3</italic>&#x003b3; promoter cloned into a plasmid vector was active while the <italic>CD3</italic>&#x003b3; gene transcripts are lost after HTLV-I infection. Thus, after HTLV-I infection, <italic>CD3</italic>&#x003b3; gene silencing could not be explained by a lack of transcription factors but potentially by a restrained accessibility to its transcriptional regulation region.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Functional analysis by transfection of the <italic>CD3</italic>&#x003b3; promoter activity in HTLV-I infected and uninfected cells</bold>. Luciferase activity was measured in uninfected CD3&#x003b3;<sup>+</sup>&#x003b4;<sup>+</sup>, HTLV-I-infected CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>+ </sup>and CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>- </sup>WE17/10 cells after 40 h and normalized to activity from the internal <italic>Renilla </italic>control. Expression of the wild-type <italic>CD3</italic>&#x003b3;promoter constructs (pH &#x003b3;3-wt) was measured in comparison to the negative control basic vector: (pGL3-BV) set to one. The pGL3 promoter vector (pGL3-PV) was used as a positive control. The results represent at least three individual experiments, each performed in triplicate.</p></caption><graphic xlink:href="1743-422X-4-85-2"/></fig></sec><sec><title>Chromatin studies: analysis of DNase I hypersensitivity sites in the CD3&#x003b3;/CD3&#x003b4; gene region</title><p>The human <italic>CD3</italic>&#x003b3;, <italic>CD3</italic>&#x003b4; and <italic>CD3</italic>&#x003b5; genes are located in a 50 kb cluster on chromosome 11q23, with <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; positioned head-to-head and separated by 1.6 kb. DNase I hypersensitivity experiments using probes designed to specifically detect the <italic>CD3</italic>&#x003b3; promoter, <italic>CD3</italic>&#x003b4; promoter or <italic>CD3</italic>&#x003b4; enhancer (an enhancer for the <italic>CD3</italic>&#x003b3; gene has not been identified yet) revealed that in uninfected (positive control) and HTLV-I infected CD3&#x003b3;<sup>+</sup>&#x003b4;<sup>+ </sup>cells all three DNase I hypersensitive sites (DHS) are readily discernible (Figure <xref ref-type="fig" rid="F3">3</xref>; relative surface CD3 expression and transcript levels are shown in Table <xref ref-type="table" rid="T1">1</xref>). In contrast, in CD3&#x003b3;<sup>lo</sup>&#x003b4;<sup>+ </sup>cells, the <italic>CD3</italic>&#x003b3;promoter DHS site is weakly detectable while the <italic>CD3</italic>&#x003b4; promoter and enhancer DHS sites are still clearly evident. In HTLV-I infected CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>- </sup>cells, the DHS sites corresponding to all three transcriptional control regions show no open chromatin in this region similar to the B cell line GM-607 used as a negative control. Taken all together our results suggest a potential chromatin remodeling process taking place after HTLV-I infection associated to the CD3 locus silencing.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>DNase I hypersensitivity of <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; genes regulatory regions after HTLV-I infection</bold>. DNase I hypersensitivity experiments using probes designed to specifically detect the <italic>CD3</italic>&#x003b3; promoter, <italic>CD3</italic>&#x003b4; promoter or <italic>CD3</italic>&#x003b4; enhancer, indicated on the Y axis. DNA was digested with increasing concentrations of DNase I (increasing from left to right in each panel) and extracted from uninfected CD3&#x003b3;<sup>+</sup>&#x003b4;<sup>+ </sup>cells and HTLV-I CD3&#x003b3;<sup>+</sup>&#x003b4;<sup>+</sup>, CD3&#x003b3;<sup>lo</sup>&#x003b4;<sup>+</sup>, and CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>- </sup>cells. The B cell (CD3 negative) and HIV-1 CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>+ </sup>cell lines were used as controls. The various cell lines are indicated on the X axis. The level of surface TCR/CD3 expression and relative CD3 gene transcripts for each cell line is shown in Table I.</p></caption><graphic xlink:href="1743-422X-4-85-3"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>TCR/CD3 expression in cells used for the DNase I hypersensitivity assay</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>Surface TCR/CD3 (flow cytometry)</bold></td><td align="left"><bold>mRNA transcripts (real-time RT-PCR)</bold></td><td></td></tr></thead><tbody><tr><td align="left"><bold>Cells</bold></td><td align="left"><bold>CD3<sup>+ </sup>cells</bold></td><td align="left"><bold>CD3&#x003b3;</bold></td><td align="left"><bold>CD3&#x003b4; </bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">uninfected</td><td align="left">100%</td><td align="left">100%</td><td align="left">100%</td></tr><tr><td align="left">HTLV-I &#x003b3;<sup>+</sup>&#x003b4;<sup>+</sup></td><td align="left">98%</td><td align="left">85%</td><td align="left">70%</td></tr><tr><td align="left">HTLV-I &#x003b3;<sup>lo</sup>&#x003b4;<sup>+</sup></td><td align="left">55%</td><td align="left">13%</td><td align="left">44%</td></tr><tr><td align="left">HTLV-I &#x003b3;<sup>-</sup>&#x003b4;<sup>-</sup></td><td align="left">0%</td><td align="left">0%</td><td align="left">0%</td></tr><tr><td align="left">B cell control</td><td align="left">0%</td><td align="left">0%</td><td align="left">0%</td></tr><tr><td align="left">HIV-1 &#x003b3;<sup>-</sup>&#x003b4;<sup>+ </sup>control</td><td align="left">0%</td><td align="left">0%</td><td align="left">70%</td></tr></tbody></table></table-wrap></sec><sec><title>Chromatin studies: CHIP experiments</title><p>The h<italic>CD3</italic>&#x003b3; promoter is lymphoid specific, initiates transcription from multiple start sites, and contains two core promoters capable of recruiting the general transcription machinery through specificity protein (Sp)-binding motifs, with an Initiator (Inr) element present in the primary core promoter[<xref ref-type="bibr" rid="B23">23</xref>]. EMSA experiments showed that the complex binding to the Sp&#x003b3;<sub><bold>1</bold></sub>/CD3&#x003b3;<sub><bold>Inr</bold></sub>[<xref ref-type="bibr" rid="B23">23</xref>] wild-type probe was the same in the nuclear extracts from CD3<sup>+ </sup>uninfected WE17/10 or from CD3<sup>- </sup>HTLV-I infected WE17/10 cells (Figure <xref ref-type="fig" rid="F4">4A</xref>). After HTLV-I infection the <italic>in vitro </italic>binding of transcription factor was apparently not affected in the CD3<sup>- </sup>HTLV-I infected WE17/10 cells. We analyzed by CHIP the accessibility of the chromatin in the <italic>CD3</italic>&#x003b3; putative promoter area to the transcriptional machinery after HTLV-I infection. An obvious reduction in accessibility for Sp1, Sp3 and TFIID was observed in CD3<sup>- </sup>HTLV-I infected WE17/10 cells in comparison with CD3<sup>+ </sup>uninfected (Figure <xref ref-type="fig" rid="F4">4B</xref>).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Transcription factor accessibility to the <italic>CD3</italic>&#x003b3; promoter after HTLV-I infection</bold>. <italic>A</italic>,<italic>In vitro </italic>binding to the Sp&#x003b3;<sub><bold>1</bold></sub>/CD3&#x003b3;<sub><bold>Inr </bold></sub>[22] wild-type probe was examined in EMSA assay using nuclear extracts from TCR/CD3<sup>+ </sup>uninfected WE17/10 and CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>- </sup>HTLV-I infected WE17/10 cells. <italic>B</italic>, ChIP assay using anti-Sp1, anti-Sp2, anti-Sp3, anti-TFIID, to study the <italic>in vivo </italic>binding to the sequence surrounding the Sp&#x003b3;<sub><bold>1</bold></sub>/CD3&#x003b3;<sub><bold>Inr </bold></sub>motif in TCR/CD3<sup>+</sup>uninfected and in CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>- </sup>HTLV-I infected WE17/10 cells.</p></caption><graphic xlink:href="1743-422X-4-85-4"/></fig></sec><sec><title>Treatment with TSA/AZA rescued CD3 mRNA in CD3<sup>- </sup>HTLV-I infected WE17/10 cells</title><p>Treatment of HTLV-I-infected WE17/10 with the histone deacetylase inhibitor (HDACi) trichostatin A in association with the DNA-methylation inhibitor 5' deoxy-azacytidine rescued <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; transcription as assessed by RT-PCR.</p><p>Histone H4 hyperacetylation is a typical feature of active transcription; we therefore analyzed chromatin hyperacetylation as well as the binding of HDAC in the <italic>CD3</italic>&#x003b3; promoter by comparing TCR/CD3<sup>+ </sup>uninfected, untreated and TSA/AZA treated TCR/CD3<sup>- </sup>HTLV-I infected WE17/10 cells (Figure <xref ref-type="fig" rid="F5">5B</xref>). We show that histone hyperacetylation is detectable in CD3<sup>+ </sup>uninfected WE17/10 cells and TSA/AZA treated CD3<sup>- </sup>HTLV-I infected WE17/10 cells, but absent in untreated CD3<sup>- </sup>HTLV-I infected WE17/10 cells. Moreover, <italic>in vivo </italic>binding of HDAC to the <italic>CD3</italic>&#x003b3; core promoter is more abundant in CD3<sup>- </sup>HTLV-I infected compared to CD3<sup>+ </sup>uninfected WE17/10 cells and TSA treated CD3<sup>- </sup>HTLV-I infected WE17/10 cells.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>TSA/AZA treatment of HTLV-I infected WE17/10 cells</bold>. <italic>A</italic>, Representative ethidium bromide-stained gels of <italic>CD3</italic>&#x003b3;, <italic>CD3</italic>&#x003b4; and GAPDH (endogenous control) RT-PCR products from untreated HTLV-I infected CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>lo</sup>, TSA/AZA HTLV-I infected CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>lo </sup>(treated for 72 hours with 4 &#x003bc;M of 5'AZA and for 18 hours with 500 nM of TSA) and uninfected untreated WE17/10 cells. <italic>B</italic>, ChIP assay using anti-Ac-H4 and anti-HDAC to study the <italic>in vivo </italic>binding to the sequence surrounding the Sp&#x003b3;<sub><bold>1</bold></sub>/CD3&#x003b3;<sub><bold>Inr </bold></sub>motif in <sup>TXP/X&#x00394;3+ </sup>uninfected and in untreated and TSA/AZA treated CD3&#x003b3;<sup>-</sup>&#x003b4;<sup>lo </sup>HTLV-I infected WE17/10 cells.</p></caption><graphic xlink:href="1743-422X-4-85-5"/></fig></sec></sec><sec><title>Discussion</title><p>The T-cell receptor (TCR)/CD3 complex is the keystone of the antigen-specific immune response. Infection by HTLV-I has been shown to ultimately downregulate <italic>CD3</italic>&#x003b3;, <italic>CD3</italic>&#x003b4;, <italic>CD3</italic>&#x003b5;, and <italic>CD3</italic>&#x003b6; gene transcripts leading to a CD3<sup>- </sup>surface phenotype after 200 days of <italic>in vitro </italic>infection[<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]; however, the sequence of gene loss has not been investigated. We have shown previously that HIV-1 [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B17">17</xref>] and HIV-2[<xref ref-type="bibr" rid="B18">18</xref>] associated loss of CD3 expression was characterized by an initial reduction in <italic>CD3</italic>&#x003b3; gene transcripts. Moreover, infected CD4<sup>+ </sup>T-cells from patients with ATLL are routinely characterized as having a CD3<sup>- </sup>or CD3<sup>low </sup>phenotype [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. The viral load and the natural history of HTLV-I has been studied over 10 years[<xref ref-type="bibr" rid="B30">30</xref>] in infected individuals. Interestingly, their figures indicate that HTLV-I+ cells have a very weak contribution to the total number of CD3<sup>+ </sup>cells. Therefore, it is not surprising that some groups did not find a decrease when looking at the total population of T-cells in patients post HTLV-I infection.</p><p>In this study, we investigated proviral integration, viral gene expression, CD3 surface density, CD3 gene transcription and chromatin structure over a period of time of three years post HTLV-I infection of the WE17/10 cell line. We found that HTLV-I <italic>in vitro </italic>infection leads to progressive downmodulation of TCR/CD3 complexes from the cell surface following a pattern of decreasing surface density reminiscent of that observed for HIV-1[<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>] and HIV-2[<xref ref-type="bibr" rid="B18">18</xref>], except for its slower kinetics. There is an altered regulation of gene expression affecting initially and more specifically the <italic>CD3</italic>&#x003b3; gene. To ensure that this phenomenon was not restricted to our experimental setting and the utilized cell line, we have tested a number of well-established HTLV-I infected CD4+ cell lines and found a general down modulation of TCR/CD3 surface expression in comparison to their uninfected counterpart.</p><p>However in contrast to the selective targeting of <italic>CD3</italic>&#x003b3; by HIV[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B18">18</xref>], HTLV-I infection represses in a sequential manner the expression of all four CD3 genes, a distinction obvious at several stages post-infection. Quantification of CD3 gene transcripts in HTLV-I infected cells expressing ~70% of the normal number of surface TCR/CD3 complexes contain only 20% <italic>CD3</italic>&#x003b3;, 48% <italic>CD3</italic>&#x003b4;, 62% <italic>CD3</italic>&#x003b5; and 75% <italic>CD3</italic>&#x003b6; gene transcripts. This extensive loss of <italic>CD3</italic>&#x003b3; transcripts prior to significant TCR/CD3 down-modulation was similar to what we have observed previously for TCR/CD3 loss after HIV-I infection[<xref ref-type="bibr" rid="B17">17</xref>]. These data explain why the progression, viewed from the cell surface, appears to be very slow by showing that transcriptional downmodulation is actually initiated early after infection with a considerable and rapid erosion of transcripts until a threshold is reached where the normal number of complete TCR/CD3 complexes can no longer be assembled and exported to the cell surface [<xref ref-type="bibr" rid="B31">31</xref>]. Although the complete loss of <italic>CD3</italic>&#x003b3; parallels the receptor negative phenotype in cell lines infected with both viruses, CD3<sup>- </sup>HTLV-I infected cells continue to progressively loosing expression of the remaining CD3 genes, with <italic>CD3</italic>&#x003b4; transcripts being absent at 29 months p.i and about ~25% <italic>CD3</italic>&#x003b5; and <italic>CD3</italic>&#x003b6; transcripts being still expressed at 3 years p.i. In contrast, HIV-1 infected cells maintain <italic>CD3</italic>&#x003b4;, <italic>CD3</italic>&#x003b5; and <italic>CD3</italic>&#x003b6; transcripts at &#x0003e;75% of normal levels in the presence of steadily decreasing <italic>CD3</italic>&#x003b3; transcripts. Our data thus reveal that while both HIV-1 and HTLV-I target the expression of the CD3 genes, remarkably they appear to accomplish this task with distinct kinetics.</p><p>Importantly, we also observed that, in contrast with HIV infected cells, an in vitro selection of certain clones occurs, as demonstrated in Fig <xref ref-type="fig" rid="F1">1</xref>, the cells with the lowest CD3 expression growing more rapidly, as we have observed it by comparing the growth speed of cell frozen at different stage of CD3 expression, then put back in culture (data not shown).</p><p>The human <italic>CD3</italic>&#x003b3;, <italic>CD3</italic>&#x003b4; and <italic>CD3</italic>&#x003b5; genes, located together on chromosome 11q23, are highly homologous due to their common ancestry[<xref ref-type="bibr" rid="B32">32</xref>], while the human <italic>CD3</italic>&#x003b6; gene is located on chromosome 1 and has no apparent sequence homology with the other CD3 genes. It is therefore remarkable that all four genes are sequentially targeted in HTLV-I infected cells. Previous studies investigating the role of individual CD3 chains in thymopoiesis suggest that a mechanism exists for controlling access to the <italic>CD3</italic>&#x003b3;, <italic>CD3</italic>&#x003b4; and <italic>CD3</italic>&#x003b5; gene cluster. Disruption of the <italic>CD3</italic>&#x003b5; gene by insertion of a neomycin cassette in place of either exon 5[<xref ref-type="bibr" rid="B30">30</xref>], exons 5 and 6[<xref ref-type="bibr" rid="B33">33</xref>] or the promoter plus exons 1 and 2[<xref ref-type="bibr" rid="B34">34</xref>] left CD3&#x003b5;<sup>-/- </sup>mice who did not only show a <italic>CD3</italic>&#x003b5; deficiency, but also underwent a significant inhibition of <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; genes transcription. Expression of <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; could be restored in CD3&#x003b5;<sup>-/- </sup>mice by deletion of the neomycin cassette using <italic>in vivo </italic>recombination but not by transgenic reconstitution of CD3&#x003b5; protein expression[<xref ref-type="bibr" rid="B35">35</xref>]. Furthermore, insertion of the same neomycin cassette in the contiguous <italic>CD3</italic>&#x003b3; [<xref ref-type="bibr" rid="B36">36</xref>] or <italic>CD3</italic>&#x003b4; [<xref ref-type="bibr" rid="B37">37</xref>] genes had no effect on transcription of their other two neighboring <italic>CD3 </italic>genes. It has been reported that the coding sequence of <italic>neo </italic>gene can act as a transcriptional silencer[<xref ref-type="bibr" rid="B38">38</xref>], which suggests that <italic>neo </italic>insertion in <italic>CD3</italic>&#x003b5; potentially functions as an insulator by separating <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; genes from a putative locus control region. Taken altogether, these data indicate the existence of a mechanism for the global control of the 11q23 CD3 genes cluster that is likely to be critical in modulating the expression of these genes during the early stages of T-cell commitment. Similar cellular factors may also be involved in controlling the <italic>CD3</italic>&#x003b6; gene to ensure its coordinate expression with the other CD3 genes during T-cell differentiation and development.</p><p>However, by transient transfection we observed that <italic>CD3</italic>&#x003b3; expression could be restored in HTLV-I infected cells lacking endogenous <italic>CD3</italic>&#x003b3; expression. This demonstrates that the loss of CD3&#x003b3; is not due to a defect in factors binding to the CD3&#x003b3; promoter region and rather suggests a lack of accessibility of these factors to the promoter regions in HTLVI infected cells. We further demonstrated that the loss of <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; transcripts is associated with progressive closure of the <italic>CD3</italic>&#x003b3; promoter DHS followed by the <italic>CD3</italic>&#x003b4; promoter and enhancer DHS. Modification in the corresponding DHS occurred in tandem with the reduction and loss of <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; gene expression p.i.</p><p>In addition, we showed a reduction <italic>in vivo </italic>binding of Sp1, Sp3 and TFIID to the <italic>CD3</italic>&#x003b3; core promoter region in CD3<sup>- </sup>HTLV-I infected WE17/10 cells in comparison with TCR/CD3<sup>+ </sup>uninfected cells, while the <italic>in vitro </italic>binding was not affected. It has been shown that Sp1 and Sp3 transcription factor binding to TRE-I repeat III participates in the regulation of HTLV-I viral gene expression[<xref ref-type="bibr" rid="B39">39</xref>]. On the other hand, epigenetic mechanisms are responsible of HTLV-I-genes transcriptional silencing[<xref ref-type="bibr" rid="B40">40</xref>].</p><p>Histone H4 hyper-acetylation is a typical feature of active transcription. Histone H4 hyperacetylation was reduced and binding of HDAC to the <italic>CD3</italic>&#x003b3; core promoter was more abundant in CD3<sup>- </sup>HTLV-I infected compared to CD3<sup>+ </sup>uninfected WE17/10 cells. As expected, treatment with the histone deacetylase inhibitor (HDAC) trichostatin A in association with the DNA-methylation inhibitor 5' deoxy-azacytidine reestablished the H4 hyperacetylation status and reduced the HDAC binding to the <italic>CD3</italic>&#x003b3; core promoter and rescued the transcription of <italic>CD3</italic>&#x003b3; and <italic>CD3</italic>&#x003b4; in the CD3<sup>- </sup>HTLV-I infected. This result reemphasizes that an epigenetic mechanism is at work to downmodulate the four <italic>CD3 </italic>genes after HTLV-I infection. We recently started a study aiming at unraveling the molecular determinants that coordinate the successive downregulation of the four <italic>CD3 </italic>genes.</p><p>In a previous work we have shown that HTLV-I infection of WE17/10 CD4<sup>+</sup>cell line leads to progressive alteration of Ca<sup>++ </sup>influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation[<xref ref-type="bibr" rid="B10">10</xref>]. Since dysregulation of calcium flux after T-cell activation can be one of the consequences of the lack of TCR/CD3 expression[<xref ref-type="bibr" rid="B11">11</xref>] the loss of TCR/CD3 expression could be of significance in the progression of HTLV-1 mediated malignant disease.</p></sec><sec><title>Conclusion</title><p>We conclude that HTLV-I expression initiates a process leading to several phenomena, among which a progressive loss of TCR/CD3 by epigenetic mechanisms. These modifications persist after HTLV-I genes are silenced through a mechanism that we have started to investigate. This eventually leads to a CD3<sup>-</sup>, CD7<sup>- </sup>phenotype associated with perturbation of calcium fluxes and constitutive activation of PI3 kinase, which prevents apoptosis and augments growth of the infected cells. The mechanism by which these phenomena continue after the loss of viral gene expression will be the subject of further studies, as well as determining whether CD3 progressive loss is an epiphenomenon or a causal event in the process of eventual malignant transformation.</p></sec><sec><title>Abbreviations</title><p>HTLV-I, human T-cell leukemia virus type I; ATL, adult T cell leukemia/lymphoma; NF-&#x003ba;B, nuclear factor kappa-B; NFAT, nuclear factor of activated T cell; HBZ, HTLV-I bZIP factor; TCR, T cell receptor; HIV, human immunodeficiency virus; DHS, DNase I hypersensitive site; EF-1-&#x003b1;, eukaryotic translation elongation factor1 &#x003b1;; MLN51, cancer susceptibility candidate 3.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>HA conceived this project and carried out most of experiments in Figs. <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>, <xref ref-type="fig" rid="F3">3</xref>, <xref ref-type="fig" rid="F4">4</xref>. BB participated in the design of the study and performed the CHIP experiments. GD carried out the DNase hypersensitivity assays in fig <xref ref-type="fig" rid="F5">5</xref>. GM participated to the Real time RT-PCR experiments. MMoschitta participated in the constructs of the plasmid used in the transfection assay. MMerimi contributed to the TSA/AZA treatment assay. AB, PM and KW participated in the study design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>CD3 expression on the surface of HTLV-I-infected cells. We have tested the HTLV-I infected cell lines MT-2, C91, WE/HTLV and an ATLL derived cell line PaBe for their TCR/CD3 surface expression. All the cells had a CD3<sup>- </sup>or CD3<sup>low </sup>phenotype.</p></caption><media xlink:href="1743-422X-4-85-S1.png" mimetype="image" mime-subtype="png"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank the Belgian Fonds National de la Recherche Scientifique (FNRS and T&#x000e9;l&#x000e9;vie), Friends of the Bordet Institute, and Fonds David and Alice Van Buuren for their support. Haidar AKL is a FNRS scientific collaborator. Bassam Badran is a FNRS post-doctoral researcher.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeang</surname><given-names>KT</given-names></name></person-group><article-title>Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: cellular signaling through NF-kappa B</article-title><source>Cytokine Growth Factor Rev</source><year>2001</year><volume>12</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">11325603</pub-id><pub-id pub-id-type="doi">10.1016/S1359-6101(00)00028-9</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamsoul</surname><given-names>I</given-names></name><name><surname>Lodewick</surname><given-names>J</given-names></name><name><surname>Lebrun</surname><given-names>S</given-names></name><name><surname>Brasseur</surname><given-names>R</given-names></name><name><surname>Burny</surname><given-names>A</given-names></name><name><surname>Gaynor</surname><given-names>RB</given-names></name><name><surname>Bex</surname><given-names>F</given-names></name></person-group><article-title>Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus tax oncoprotein</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><fpage>10391</fpage><lpage>10406</lpage><pub-id pub-id-type="pmid">16287853</pub-id><pub-id pub-id-type="doi">10.1128/MCB.25.23.10391-10406.2005</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nasr</surname><given-names>R</given-names></name><name><surname>Chiari</surname><given-names>E</given-names></name><name><surname>El-Sabban</surname><given-names>M</given-names></name><name><surname>Mahieux</surname><given-names>R</given-names></name><name><surname>Kfoury</surname><given-names>Y</given-names></name><name><surname>Abdulhay</surname><given-names>M</given-names></name><name><surname>Yazbeck</surname><given-names>V</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>de Th&#x000e9;</surname><given-names>H</given-names></name><name><surname>Pique</surname><given-names>C</given-names></name><name><surname>Bazarbachi</surname><given-names>A</given-names></name></person-group><article-title>Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>4021</fpage><lpage>4029</lpage><pub-id pub-id-type="pmid">16424386</pub-id><pub-id pub-id-type="doi">10.1182/blood-2005-09-3572</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albrecht</surname><given-names>B</given-names></name><name><surname>D'Souza</surname><given-names>CD</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Tridandapani</surname><given-names>S</given-names></name><name><surname>Coggeshall</surname><given-names>KM</given-names></name><name><surname>Lairmore</surname><given-names>MD</given-names></name></person-group><article-title>Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory protein p12(I)</article-title><source>J Virol</source><year>2002</year><volume>76</volume><fpage>3493</fpage><lpage>3501</lpage><pub-id pub-id-type="pmid">11884573</pub-id><pub-id pub-id-type="doi">10.1128/JVI.76.7.3493-3501.2002</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Albrecht</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>PL</given-names></name><name><surname>Lairmore</surname><given-names>MD</given-names></name></person-group><article-title>A conserved calcineurin-binding motif in human T lymphotropic virus type 1 p12I functions to modulate nuclear factor of activated T cell activation</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>15550</fpage><lpage>15557</lpage><pub-id pub-id-type="pmid">12601010</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M210210200</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>J</given-names></name><name><surname>Ohshima</surname><given-names>T</given-names></name><name><surname>Isono</surname><given-names>O</given-names></name><name><surname>Shimotohno</surname><given-names>K</given-names></name></person-group><article-title>HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>1001</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">15592508</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208297</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yokote</surname><given-names>T</given-names></name><name><surname>Akioka</surname><given-names>T</given-names></name><name><surname>Oka</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Yamano</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Tsuji</surname><given-names>M</given-names></name><name><surname>Hanafusa</surname><given-names>T</given-names></name></person-group><article-title>Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating</article-title><source>Am J Clin Pathol</source><year>2005</year><volume>124</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">16040289</pub-id><pub-id pub-id-type="doi">10.1309/KEN4-MXM5-Y9A1-GEMP</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>H</given-names></name><name><surname>Takatsuki</surname><given-names>K</given-names></name></person-group><article-title>Specific decrease in T3 antigen density in adult T-cell leukaemia cells: I. Flow microfluorometric analysis</article-title><source>Br J Cancer</source><year>1984</year><volume>50</volume><fpage>843</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">6238617</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>M</given-names></name><name><surname>Hattori</surname><given-names>T</given-names></name><name><surname>Chosa</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>H</given-names></name><name><surname>Kuwata</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Uchiyama</surname><given-names>T</given-names></name><name><surname>Takatsuki</surname><given-names>K</given-names></name></person-group><article-title>T3 surface molecules on adult T cell leukemia cells are modulated in vivo</article-title><source>Blood</source><year>1986</year><volume>67</volume><fpage>1070</fpage><lpage>1076</lpage><pub-id pub-id-type="pmid">2869803</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akl</surname><given-names>H</given-names></name><name><surname>Badran</surname><given-names>BM</given-names></name><name><surname>Zein</surname><given-names>NE</given-names></name><name><surname>Bex</surname><given-names>F</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name><name><surname>Burny</surname><given-names>A</given-names></name><name><surname>Martiat</surname><given-names>P</given-names></name></person-group><article-title>HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation</article-title><source>Leukemia</source><year>2007</year><volume>21</volume><fpage>788</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">17287851</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Deist</surname><given-names>F</given-names></name><name><surname>Thoenes</surname><given-names>G</given-names></name><name><surname>Corado</surname><given-names>J</given-names></name><name><surname>Lisowska-Grospierre</surname><given-names>B</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name></person-group><article-title>Immunodeficiency with low expression of the T cell receptor/CD3 complex. Effect on T lymphocyte activation</article-title><source>Eur J Immunol</source><year>1991</year><volume>21</volume><fpage>1641</fpage><lpage>1647</lpage><pub-id pub-id-type="pmid">1676369</pub-id><pub-id pub-id-type="doi">10.1002/eji.1830210709</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yssel</surname><given-names>H</given-names></name><name><surname>de Waal</surname><given-names>MR</given-names></name><name><surname>Duc</surname><given-names>D</given-names></name><name><surname>Blanchard</surname><given-names>D</given-names></name><name><surname>Gazzolo</surname><given-names>L</given-names></name><name><surname>de Vries</surname><given-names>JE</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><article-title>Human T cell leukemia/lymphoma virus type I infection of a CD4+ proliferative/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells</article-title><source>J Immunol</source><year>1989</year><volume>142</volume><fpage>2279</fpage><lpage>2289</lpage><pub-id pub-id-type="pmid">2466894</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Waal</surname><given-names>M</given-names></name><name><surname>Yssel</surname><given-names>H</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>de Vries</surname><given-names>JE</given-names></name><name><surname>Sancho</surname><given-names>J</given-names></name><name><surname>Terhorst</surname><given-names>C</given-names></name><name><surname>Alarcon</surname><given-names>B</given-names></name></person-group><article-title>Human T cell leukemia virus type I prevents cell surface expression of the T cell receptor through down-regulation of the CD3-gamma, -delta, -epsilon, and -zeta genes</article-title><source>J Immunol</source><year>1990</year><volume>145</volume><fpage>2297</fpage><lpage>2303</lpage><pub-id pub-id-type="pmid">2144550</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name><name><surname>Van de Keere</surname><given-names>F</given-names></name><name><surname>Kettmann</surname><given-names>R</given-names></name></person-group><article-title>A specific defect in CD3 gamma-chain gene transcription results in loss of T-cell receptor/CD3 expression late after human immunodeficiency virus infection of a CD4+ T-cell line</article-title><source>Proc Natl Acad Sci USA</source><year>1990</year><volume>87</volume><fpage>6713</fpage><lpage>6717</lpage><pub-id pub-id-type="pmid">2144349</pub-id><pub-id pub-id-type="doi">10.1073/pnas.87.17.6713</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name><name><surname>Delmelle-Wibaut</surname><given-names>C</given-names></name><name><surname>Segura-Zapata</surname><given-names>I</given-names></name><name><surname>Janssens</surname><given-names>M</given-names></name><name><surname>Willems</surname><given-names>L</given-names></name><name><surname>Kettmann</surname><given-names>R</given-names></name></person-group><article-title>Modulation of CD3-gamma gene expression after HIV type 1 infection of the WE17/10 T cell line is progressive and occurs in concert with decreased production of viral p24 antigen</article-title><source>AIDS Res Hum Retroviruses</source><year>1996</year><volume>12</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">8744582</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name><name><surname>Furtado</surname><given-names>M</given-names></name><name><surname>Burny</surname><given-names>A</given-names></name><name><surname>Wolinsky</surname><given-names>SM</given-names></name></person-group><article-title>Down-modulation of TCR/CD3 surface complexes after HIV-1 infection is associated with differential expression of the viral regulatory genes</article-title><source>Eur J Immunol</source><year>2001</year><volume>31</volume><fpage>969</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">11298321</pub-id><pub-id pub-id-type="doi">10.1002/1521-4141(200104)31:4&#x0003c;969::AID-IMMU969&#x0003e;3.0.CO;2-2</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Badran</surname><given-names>BM</given-names></name><name><surname>Wolinsky</surname><given-names>SM</given-names></name><name><surname>Burny</surname><given-names>A</given-names></name><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name></person-group><article-title>Identification of three NFAT binding motifs in the 5'-upstream region of the human CD3gamma gene that differentially bind NFATc1, NFATc2, and NF-kappa B p50</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>47136</fpage><lpage>47148</lpage><pub-id pub-id-type="pmid">12374807</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M206330200</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segura</surname><given-names>I</given-names></name><name><surname>Delmelle-Wibaut</surname><given-names>C</given-names></name><name><surname>Janssens</surname><given-names>M</given-names></name><name><surname>Cleuter</surname><given-names>Y</given-names></name><name><surname>Van den Broeke</surname><given-names>A</given-names></name><name><surname>Kettmann</surname><given-names>R</given-names></name><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name></person-group><article-title>Human Immunodeficiency Virus Type 2 Produces a Defect in CD3-gamma Gene Transcripts Similar to That Observed for Human Immunodeficiency Virus Type 1</article-title><source>J Virol</source><year>1999</year><volume>73</volume><fpage>5207</fpage><lpage>5213</lpage><pub-id pub-id-type="pmid">10233990</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name><name><surname>Badran</surname><given-names>BM</given-names></name><name><surname>Ravoet</surname><given-names>M</given-names></name><name><surname>Zerghe</surname><given-names>A</given-names></name><name><surname>Burny</surname><given-names>A</given-names></name><name><surname>Martiat</surname><given-names>P</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name><name><surname>Roufosse</surname><given-names>F</given-names></name><name><surname>Sibille</surname><given-names>C</given-names></name></person-group><article-title>Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome</article-title><source>Exp Hematol</source><year>2005</year><volume>33</volume><fpage>1147</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">16219537</pub-id><pub-id pub-id-type="doi">10.1016/j.exphem.2005.06.027</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hannibal</surname><given-names>MC</given-names></name><name><surname>Markovitz</surname><given-names>DM</given-names></name><name><surname>Clark</surname><given-names>N</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><article-title>Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals</article-title><source>J Virol</source><year>1993</year><volume>67</volume><fpage>5035</fpage><lpage>5040</lpage><pub-id pub-id-type="pmid">8331739</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>I</given-names></name><name><surname>Kubonishi</surname><given-names>I</given-names></name><name><surname>Yoshimoto</surname><given-names>S</given-names></name><name><surname>Akagi</surname><given-names>T</given-names></name><name><surname>Ohtsuki</surname><given-names>Y</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><name><surname>Hinuma</surname><given-names>Y</given-names></name></person-group><article-title>Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells</article-title><source>Nature</source><year>1981</year><volume>294</volume><fpage>770</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">6275274</pub-id><pub-id pub-id-type="doi">10.1038/294770a0</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dube</surname><given-names>D</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name><name><surname>Saksena</surname><given-names>N</given-names></name><name><surname>Bryz-gornia</surname><given-names>V</given-names></name><name><surname>Mendelson</surname><given-names>J</given-names></name><name><surname>Love</surname><given-names>J</given-names></name><name><surname>Arnold</surname><given-names>C</given-names></name><name><surname>Spicer</surname><given-names>T</given-names></name><name><surname>Dube</surname><given-names>S</given-names></name><name><surname>Glaser</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Jacobsen</surname><given-names>S</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name><name><surname>Del Pino</surname><given-names>N</given-names></name><name><surname>Quiruelas</surname><given-names>S</given-names></name><name><surname>Poiez</surname><given-names>B</given-names></name></person-group><article-title>T Cell-specific Expression of the Murine CD3delta Promoter</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>47898</fpage><lpage>47906</lpage><pub-id pub-id-type="pmid">12324448</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M201025200</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Badran</surname><given-names>BM</given-names></name><name><surname>Kunstman</surname><given-names>K</given-names></name><name><surname>Stanton</surname><given-names>J</given-names></name><name><surname>Moschitta</surname><given-names>M</given-names></name><name><surname>Zerghe</surname><given-names>A</given-names></name><name><surname>Akl</surname><given-names>H</given-names></name><name><surname>Burny</surname><given-names>A</given-names></name><name><surname>Wolinsky</surname><given-names>SM</given-names></name><name><surname>Willard-Gallo</surname><given-names>KE</given-names></name></person-group><article-title>Transcriptional Regulation of the Human CD3{gamma} Gene: The TATA-Less CD3{gamma} Promoter Functions via an Initiator and Contiguous Sp-Binding Elements</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><fpage>6238</fpage><lpage>6249</lpage><pub-id pub-id-type="pmid">15879122</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cockerill</surname><given-names>PN</given-names></name></person-group><article-title>Identification of DNaseI hypersensitive sites within nuclei</article-title><source>Methods Mol Biol</source><year>2000</year><volume>130</volume><fpage>29</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">10589419</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geisler</surname><given-names>C</given-names></name></person-group><article-title>Failure to synthesize the CD3-gamma chain. Consequences for T cell antigen receptor assembly, processing, and expression</article-title><source>J Immunol</source><year>1992</year><volume>148</volume><fpage>2437</fpage><lpage>2445</lpage><pub-id pub-id-type="pmid">1532815</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Gaffney</surname><given-names>P</given-names></name><name><surname>Mortari</surname><given-names>F</given-names></name><name><surname>Miller</surname><given-names>JS</given-names></name></person-group><article-title>CD3 gamma, CD3 delta, and CD3 zeta mRNA in adult human marrow hematopoietic progenitors correlates with surface CD2 and CD7 expression</article-title><source>Exp Hematol</source><year>1996</year><volume>24</volume><fpage>1402</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">8913286</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamalainen</surname><given-names>HK</given-names></name><name><surname>Tubman</surname><given-names>JC</given-names></name><name><surname>Vikman</surname><given-names>S</given-names></name><name><surname>Kyrola</surname><given-names>T</given-names></name><name><surname>Ylikoski</surname><given-names>E</given-names></name><name><surname>Warrington</surname><given-names>JA</given-names></name><name><surname>Lahesmaa</surname><given-names>R</given-names></name></person-group><article-title>Identification and validation of endogenous reference genes for expression profiling of T helper cell differentiation by quantitative real-time RT-PCR</article-title><source>Anal Biochem</source><year>2001</year><volume>299</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11726185</pub-id><pub-id pub-id-type="doi">10.1006/abio.2001.5369</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Georgopoulos</surname><given-names>K</given-names></name><name><surname>van den</surname><given-names>EP</given-names></name><name><surname>Bier</surname><given-names>E</given-names></name><name><surname>Maxam</surname><given-names>A</given-names></name><name><surname>Terhorst</surname><given-names>C</given-names></name></person-group><article-title>A T cell-specific enhancer is located in a DNase I-hypersensitive area at the 3' end of the CD3-delta gene</article-title><source>EMBO J</source><year>1988</year><volume>7</volume><fpage>2401</fpage><lpage>2407</lpage><pub-id pub-id-type="pmid">2847918</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benovic</surname><given-names>S</given-names></name><name><surname>Kok</surname><given-names>T</given-names></name><name><surname>Stephenson</surname><given-names>A</given-names></name><name><surname>McInnes</surname><given-names>J</given-names></name><name><surname>Burrell</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>P</given-names></name></person-group><article-title>De novo reverse transcription of HTLV-1 following cell-to-cell transmission of infection</article-title><source>Virology</source><year>1998</year><volume>244</volume><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">9601500</pub-id><pub-id pub-id-type="doi">10.1006/viro.1998.9111</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwaan</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Chafets</surname><given-names>DM</given-names></name><name><surname>Nass</surname><given-names>C</given-names></name><name><surname>Newman</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Garatty</surname><given-names>G</given-names></name><name><surname>Murphy</surname><given-names>ML</given-names></name></person-group><article-title>Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data</article-title><source>J Infect Dis</source><year>2006</year><volume>194</volume><fpage>1557</fpage><lpage>1564</lpage><pub-id pub-id-type="pmid">17083040</pub-id><pub-id pub-id-type="doi">10.1086/508899</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>B</given-names></name><name><surname>Alibaud</surname><given-names>L</given-names></name><name><surname>Huchenq-Champagne</surname><given-names>A</given-names></name><name><surname>Arnaud</surname><given-names>J</given-names></name><name><surname>Toribio</surname><given-names>ML</given-names></name><name><surname>Constans</surname><given-names>J</given-names></name></person-group><article-title>Some hints concerning the shape of T-cell receptor structures</article-title><source>Scand J Immunol</source><year>2002</year><volume>55</volume><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">11896927</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-3083.2002.01044.x</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gobel</surname><given-names>TW</given-names></name><name><surname>Dangy</surname><given-names>JP</given-names></name></person-group><article-title>Evidence for a stepwise evolution of the CD3 family</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><fpage>879</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">10623835</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malissen</surname><given-names>M</given-names></name><name><surname>Gillet</surname><given-names>A</given-names></name><name><surname>Ardouin</surname><given-names>L</given-names></name><name><surname>Bouvier</surname><given-names>G</given-names></name><name><surname>Trucy</surname><given-names>J</given-names></name><name><surname>Ferrier</surname><given-names>P</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name></person-group><article-title>Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene</article-title><source>EMBO J</source><year>1995</year><volume>14</volume><fpage>4641</fpage><lpage>4653</lpage><pub-id pub-id-type="pmid">7588594</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeJarnette</surname><given-names>JB</given-names></name><name><surname>Sommers</surname><given-names>CL</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Woodside</surname><given-names>KJ</given-names></name><name><surname>Emmons</surname><given-names>R</given-names></name><name><surname>Katz</surname><given-names>K</given-names></name><name><surname>Shores</surname><given-names>EW</given-names></name><name><surname>Love</surname><given-names>PE</given-names></name></person-group><article-title>Specific requirement for CD3epsilon in T cell development</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>14909</fpage><lpage>14914</lpage><pub-id pub-id-type="pmid">9843989</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.25.14909</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Salio</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>D</given-names></name><name><surname>She</surname><given-names>J</given-names></name><name><surname>Terhorst</surname><given-names>C</given-names></name></person-group><article-title>Expression of a CD3 epsilon transgene in CD3 epsilon(null) mice does not restore CD3 gamma and delta expression but efficiently rescues T cell development from a subpopulation of prothymocytes</article-title><source>Int Immunol</source><year>1998</year><volume>10</volume><fpage>1777</fpage><lpage>1788</lpage><pub-id pub-id-type="pmid">9885898</pub-id><pub-id pub-id-type="doi">10.1093/intimm/10.12.1777</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haks</surname><given-names>MC</given-names></name><name><surname>Krimpenfort</surname><given-names>P</given-names></name><name><surname>Borst</surname><given-names>J</given-names></name><name><surname>Kruisbeek</surname><given-names>AM</given-names></name></person-group><article-title>The CD3gamma chain is essential for development of both the TCRalphabeta and TCRgammadelta lineages</article-title><source>EMBO J</source><year>1998</year><volume>17</volume><fpage>1871</fpage><lpage>1882</lpage><pub-id pub-id-type="pmid">9524111</pub-id><pub-id pub-id-type="doi">10.1093/emboj/17.7.1871</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dave</surname><given-names>VP</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Browne</surname><given-names>C</given-names></name><name><surname>Alarcon</surname><given-names>B</given-names></name><name><surname>Fernandez-Miguel</surname><given-names>G</given-names></name><name><surname>Lafaille</surname><given-names>J</given-names></name><name><surname>de la Hera</surname><given-names>A</given-names></name><name><surname>Tonegawa</surname><given-names>S</given-names></name><name><surname>Kappes</surname><given-names>DJ</given-names></name></person-group><article-title>CD3 delta deficiency arrests development of the alpha beta but not the gamma delta T cell lineage</article-title><source>EMBO J</source><year>1997</year><volume>16</volume><fpage>1360</fpage><lpage>1370</lpage><pub-id pub-id-type="pmid">9135151</pub-id><pub-id pub-id-type="doi">10.1093/emboj/16.6.1360</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Artelt</surname><given-names>P</given-names></name><name><surname>Grannemann</surname><given-names>R</given-names></name><name><surname>Stocking</surname><given-names>C</given-names></name><name><surname>Friel</surname><given-names>J</given-names></name><name><surname>Bartsch</surname><given-names>J</given-names></name><name><surname>Hauser</surname><given-names>H</given-names></name></person-group><article-title>The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells</article-title><source>Gene</source><year>1991</year><volume>99</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">1850711</pub-id><pub-id pub-id-type="doi">10.1016/0378-1119(91)90134-W</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Grant</surname><given-names>C</given-names></name><name><surname>Harhaj</surname><given-names>E</given-names></name><name><surname>Nonnemacher</surname><given-names>M</given-names></name><name><surname>Alefantis</surname><given-names>T</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Jain</surname><given-names>P</given-names></name><name><surname>Wigdahl</surname><given-names>B</given-names></name></person-group><article-title>Regulation of human T-cell leukemia virus type 1 gene expression by Sp1 and Sp3 interaction with TRE-1 repeat III</article-title><source>DNA Cell Biol</source><year>2006</year><volume>25</volume><fpage>262</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">16716116</pub-id><pub-id pub-id-type="doi">10.1089/dna.2006.25.262</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>Y</given-names></name><name><surname>Nosaka</surname><given-names>K</given-names></name><name><surname>Yasunaga</surname><given-names>J</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>N</given-names></name><name><surname>Okayama</surname><given-names>A</given-names></name><name><surname>Matsuoka</surname><given-names>M</given-names></name></person-group><article-title>Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms</article-title><source>Retrovirology</source><year>2005</year><volume>2</volume><fpage>64</fpage><pub-id pub-id-type="pmid">16242045</pub-id><pub-id pub-id-type="doi">10.1186/1742-4690-2-64</pub-id></citation></ref></ref-list></back></article> 